Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Food Saf (Tokyo) ; 10(3): 73-82, 2022 Sep.
Article in English | MEDLINE | ID: mdl-36237397

ABSTRACT

Hepatotoxicity associated with food-derived coumarin occurs occasionally in humans. We have, herein, assessed the data of existing clinical and nonclinical studies as well as those of in silico models for humans in order to shed more light on this association. The average intakes of food-derived coumarin are estimated to be 1-3 mg/day, while a ten-times higher level is expected in the worst-case scenarios. These levels are close to or above the tolerable daily intake suggested by a chronic study in dogs. The human internal exposure levels were estimated by a physiologically-based pharmacokinetic model with the use of virtual doses of coumarin in the amounts expected to derive from foods. Our results suggest that: (i) coumarin can be cleared rapidly via 7-hydroxylation in humans, and (ii) the plasma levels of coumarin and of its metabolite, o-hydroxyphenylacetic acid associated with hepatotoxicity, are considerably lower than those yielding hepatotoxicity in rats. Pharmacokinetic data suggest a low or negligible concern regarding a coumarin-induced hepatotoxicity in humans exposed to an average intake from foods. Detoxification of coumarin through the 7-hydroxylation, however, might vary among individuals due to genetic polymorphisms in CYP2A6 enzyme. In addition, the CYP1A2- and CYP2E1-mediated activation of coumarin can fluctuate as a result of induction caused by environmental factors. Furthermore, the daily consumption of food-contained coumarin was implicated in the potential risk of hepatotoxicity by the drug-induced liver injury score model developed by the US Food and Drug Administration. These results support the idea of the existence of human subpopulations that are highly sensitive to coumarin; therefore, a more precise risk assessment is needed. The present study also highlights the usefulness of in silico approaches of pharmacokinetics with the liver injury score model as battery components of a risk assessment.

2.
Regul Toxicol Pharmacol ; 136: 105275, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36244463

ABSTRACT

The aim of this study is to define chemical categories that can be applied to regulatory read-across assessments for repeated-dose toxicity, by classifying toxic substances based on their structures and mechanism of actions (MoAs). Hemolytic anemia, which often appears primarily, was examined as an example. An integrated database was constructed by collecting publicly available datasets on repeated-dose toxicity, in which 423 out of a total of 1518 chemicals were identified as capable of inducing hemolytic anemia. Subsequently, by grouping these chemicals based on their chemical structures and plausible MoAs on hemolytic substances, we identified the following categories: (i) anilines, (ii) nitrobenzenes, (iii) nitroanilines, (iv) dinitroanilines, (v) ethylene glycol alkyl ethers, (vi) hydroquinones, (vii) oximes, and (viii) hydrazines. In these categories, the toxicant and the measurable key events leading to hematotoxicity were identified, thereby allowing us to justify the categories and to discriminate the category substances. Moreover, toxicokinetics seems to critically affect the hemolytic levels of the category substances. Overall, the categories were validated through a comprehensive analysis of the collected information, while the utility was demonstrated by conducting a case study on the selected category. Further endeavors with this approach would attain categories for other organ toxicity endpoints.


Subject(s)
Anemia, Hemolytic , Hazardous Substances , Humans , Ethylene Glycols , Toxicokinetics , Anemia, Hemolytic/chemically induced , Risk Assessment
3.
J Toxicol Sci ; 46(11): 531-538, 2021.
Article in English | MEDLINE | ID: mdl-34719556

ABSTRACT

Developmental and reproductive toxicity (DART) is an important endpoint, and databases (DBs) are essential for evaluating the risk of untested substances using alternative methods. We have constructed a reliable and transparent DART DB, which we named DART NIHS DB, using the publicly available datasets of DART studies of industrial chemicals conducted by Japanese government ministries in accordance with the corresponding OECD test guidelines (OECD TG421 and TG422). This DB is unique because its dataset chemicals have little overlap with those of ToxRefDB, which compiles large-scale DART data, and it is reliable because the included datasets were created after reviewing the individual study reports. In DART NIHS DB, 171 of 404 substances exhibited signs of DART, which occurred during fertility and early embryonic development (49 substances), organogenesis (59 substances), and the perinatal period (161 substances). When the lowest-observed-adverse-effect level (LOAEL) of DART was compared with that of repeated-dose toxicity (RDT), 15 substances (12%) had a lower LOAEL for DART than for RDT. Of these, five substances displayed significant DART at doses of ≤ 50 mg/kg bw/day. The chemical and toxicity information in this DB will be useful for the development of stage-specific adverse outcome pathways (AOPs) via integration with mechanistic information. The whole datasets of the DB can be implemented in read-across support tools such as the OECD QSAR Toolbox, which will further lead to future integrated approaches to testing and assessment based on AOPs.


Subject(s)
Drug-Related Side Effects and Adverse Reactions , Toxicity Tests , Databases, Factual , Female , Humans , Pregnancy , Reproduction , Risk Assessment
4.
Basic Clin Pharmacol Toxicol ; 105(3): 156-66, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19486331

ABSTRACT

This (1)H nuclear magnetic resonance metabonomics study was aimed to determine urinary biomarkers of cholestasis resulting from inhibition of biliary secretion of bile or obstruction of bile flow. To inhibit biliary secretion of bile, cyclosporine A was administered to male Sprague-Dawley rats. Obstruction of bile flow was induced by administration of 4,4'-methylene dianiline, alpha-naphthylisothiocyanate or bile duct ligation. Clinical pathological and histopathological examinations were performed to confirm cholestatic injury and (1)H nuclear magnetic resonance spectral data for urine samples were analysed to determine similarities and differences in profiles of metabolites using the Spotfire. In cyclosporine A-treated groups, serum total bilirubin and bile acid were significantly increased but no remarkable hepatic histopathological-changes were observed. In 4,4'-methylene dianiline-, alpha-naphthylisothiocyanate- and bile duct ligation-treated groups, serum alkaline phosphatase, gamma-glutamyltranspeptidase and total bilirubin levels increased significantly, and hepatic histopathological-changes were observed. On urinary (1)H nuclear magnetic resonance spectral analysis, area intensities derived from 0.66 to 1.90 ppm were decreased by cyclosporine A, whereas they were increased by other treatments. These metabolites were identified using the NMR suite as bile acids, branched-chain amino acids, n-butyrate, propionate, methyl malonate and valerate. These metabolites were further investigated by K-means clustering analysis. The cluster of these metabolites is considered to be altered by cholestasis. We conclude that bile acids, valine and methyl malonate have a possibility to be urinary cholestatic biomarkers, which distinguish a difference in mechanism of toxicity. (1)H nuclear magnetic resonance metabonomics thus appears to be useful for determining the mechanisms of toxicity and can be front-loaded in drug safety evaluation and biomarker discovery.


Subject(s)
1-Naphthylisothiocyanate/toxicity , Cholestasis/chemically induced , Cyclosporine/toxicity , Aniline Compounds/metabolism , Aniline Compounds/toxicity , Animals , Biomarkers , Cholestasis/pathology , Cholestasis/urine , Cyclosporine/metabolism , Disease Models, Animal , Kidney/drug effects , Magnetic Resonance Spectroscopy , Male , Metabolomics , Rats , Rats, Sprague-Dawley
5.
Regul Toxicol Pharmacol ; 54(3): 308-13, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19467286

ABSTRACT

Acetylsalicylic acid (ASA) at single doses of 125, 250, and 500mg/kg was administered to pregnant rats on Gestation Day (GD) 10, and skeletal changes in fetuses harvested on GD 20 and pups on post-natal (PN) Day 21 were evaluated. Changes in cartilage and ossified bones identified by Alizarin Red S single-staining were compared with Alizarin Red S and Alcian Blue double-staining. By the single-staining technique, skeletal abnormalities including fused rib, incomplete ossification of the cervical arch, absent/hemicentric body of thoracic or lumbar vertebra, deformation of lumbar arch, and absent sacral arch were demonstrated in at 250 and 500mg/kg ASA on GD 20. The double-staining technique facilitated identification of additional cartilaginous changes in the vertebrae, paws, and ribs: including discontinuous rib cartilage, fused carpus, and split cartilage of thoracic centrum at same doses. Discontinuous rib cartilage and fused carpus persisted in pups until PN Day 21 demonstrating that these changes were irreversible. With use of the double-staining technique, the incidence of abnormalities at 250mg/kg were dramatically increased, thus this technique was more sensitive for identifying fetal cartilaginous and ossified skeletal changes.


Subject(s)
Abnormalities, Drug-Induced/pathology , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Aspirin/toxicity , Bone and Bones/abnormalities , Prenatal Exposure Delayed Effects/pathology , Animals , Dose-Response Relationship, Drug , Female , Male , Pregnancy , Rats , Staining and Labeling
6.
Eur J Pharmacol ; 548(1-3): 181-7, 2006 Oct 24.
Article in English | MEDLINE | ID: mdl-16973152

ABSTRACT

Dipeptidyl peptidase IV (DPP-IV) inhibitors are expected to become a useful new class of anti-diabetic agent. The aim of the present study is to characterize the in vitro and in vivo profile of E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, which is a novel imidazopyridazinone-derived DPP-IV inhibitor. E3024 inhibited recombinant human and mouse DPP-IV with IC50 values of approximately 100 nM. E3024 inhibited DPP-IV in human, mouse, rat and canine plasma with IC50 values of 140 to 400 nM. In contrast, E3024 did not inhibit DPP-8 or DPP-9 activity. Kinetic analysis indicated that E3024 is a competitive DPP-IV inhibitor. In Zucker fa/fa rats, E3024 (1 mg/kg) reduced glucose excursion after glucose load, with increases in plasma insulin and active glucagon-like peptide-1 levels. In fasted rats, this compound did not cause hypoglycemia. In a rat 4-week toxicological study, no notable changes were found at doses up to 750 mg/kg. The present preclinical studies indicate that E3024 is a novel selective DPP-IV inhibitor with anti-diabetic effects and a good safety profile.


Subject(s)
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors , Hypoglycemic Agents/pharmacology , Imidazoles/pharmacology , Protease Inhibitors/pharmacology , Pyridazines/pharmacology , Tosyl Compounds/pharmacology , Animals , Blood Glucose/analysis , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/blood , Dogs , Female , Glucagon-Like Peptide 1/blood , Humans , Hypoglycemic Agents/pharmacokinetics , Hypoglycemic Agents/toxicity , Imidazoles/pharmacokinetics , Imidazoles/toxicity , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/pathology , Male , Mice , No-Observed-Adverse-Effect Level , Protease Inhibitors/pharmacokinetics , Protease Inhibitors/toxicity , Pyridazines/pharmacokinetics , Pyridazines/toxicity , Rats , Rats, Sprague-Dawley , Rats, Wistar , Rats, Zucker , Recombinant Proteins/metabolism , Tosyl Compounds/pharmacokinetics , Tosyl Compounds/toxicity
7.
Basic Clin Pharmacol Toxicol ; 99(3): 251-60, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16930299

ABSTRACT

The efficacy of high-resolution (1)H nuclear magnetic resonance ((1)H-NMR) spectroscopy-based metabonomics was studied in a model of rat liver toxicity. Hepatotoxicities were induced in male rats using methylene dianiline, clofibrate and galactosamine. Twenty-four-hr urine from days 1 to 5 after treatment were subjected to (1)H-NMR evaluation of the biochemical effects. Blood were also taken at Days 2, 3 and 5 to examine biochemical changes associated with hepatotoxicities, and histopathological changes were evaluated at termination. Increases in liver enzymes were observed in animals treated with methylene dianiline or galactosamine, and histopathological analysis revealed changes associated with hepatobiliary damage and hepatocellular necrosis in methylene dianiline- and galactosamine-treated animals, respectively. Principal component analysis and statistical Spotfire analyses were used to visualize similarities and differences in urine biochemical profiles produced by (1)H-NMR spectra. The biochemical effects of methylene dianiline and galactosamine were characterized by elevated levels of glucose, fructose, beta-hydroxybutyrate, alanine, acetoacetate, lactate and creatine and decreased levels of hippurate, 2-oxoglutarate, citrate, succinate, trimethylamine-N-oxide, taurine and N-acetylglutamate in rat urine. Clofibrate treatment elevated the levels of N-methylnicotinamide and 3,4-dihydroxymandelate and decreased the levels of 2-oxoglutarate and N-acetylaspartate. This work shows that combinations of (1)H-NMR and pattern recognition are powerful tools in the evaluation of the biochemical effects of xenobiotics in liver.


Subject(s)
Aniline Compounds/toxicity , Chemical and Drug Induced Liver Injury , Clofibrate/toxicity , Galactosamine/toxicity , Liver Diseases/urine , Liver/drug effects , Liver/metabolism , Metabolic Networks and Pathways/drug effects , Aniline Compounds/metabolism , Animals , Clofibrate/metabolism , Galactosamine/metabolism , Liver/pathology , Liver Diseases/metabolism , Liver Diseases/pathology , Rats , Urine/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...